CARDIOVASCULAR MEDICINE

Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol

I Ferreira¹, L Dos¹, P Tornos¹, I Nicolau², G Permanyer-Miralda¹, J Soler-Soler¹

¹ Cardiology Department, Hospital Universitari Vall d’Hebron, Institut Català de la Salut, Barcelona, Spain
² Haematology Department, Hospital Universitari Vall d’Hebron

Correspondence to:
Correspondence to:
Dr I Ferreira González, Cardiology Department, Hospital Universitari Vall d’Hebron, Pge Vall d’Hebron 119-129, 08035 Barcelona, Spain;
32453ifg{at}comb.es

Objectives: To evaluate the incidence of thromboembolic and haemorrhagic events in a cohort of patients with mechanical heart valves who had to withhold acenocumarol and were treated with enoxaparin.

Design: Observational prospective study.

Setting: In hospital; after discharge, and follow up by telephone call.

Patients and methods: All consecutive patients with mechanical heart valves admitted to the authors’ hospital between May 1999 and January 2002 who had to interrupt treatment with acenocumarol and were treated with enoxaparin as an alternative to other methods were enrolled. In each patient, the following characteristics were prospectively determined: the reason for interrupting acenocumarol, demographic data, estimated global risk for thromboembolic events, international normalised ratio before starting enoxaparin treatment, number of days taking enoxaparin, and mean level of anti-Xa activity during treatment. All patients were followed up through clinical history during the hospitalisation and by telephone after discharge to detect thromboembolic events.

Main outcome measure: Presence of thromboembolic or haemorrhagic events.

Results: 82 patients were identified and followed up for a mean of 2.8 months (range 1.5–3.5 months) after discharge. 61 of them (74%) had one or more associated thromboembolic risk factors. Acenocumarol was interrupted (to perform an invasive procedure in 74 patients and because of haemorrhagic complication in 8) an average of 11.2 days (range 3–40 days). Most patients received the standard enoxaparin dose (1 mg/kg at 12 hour intervals). Mean (SD) anti-Xa activity was 0.58 (0.3) IU/ml (median 0.51). There were 8 minor and 1 major bleeding events during enoxaparin treatment. No thromboembolic complications were clinically detected during hospitalisation or during follow up (95% confidence interval 0% to 3.6%).

Conclusions: Enoxaparin may be an effective and relatively safe substitute anticoagulant for patients with mechanical heart valves who must withhold acenocumarol.

Keywords: enoxaparin; mechanical heart valve; thromboembolic risk factors; thromboembolic events; haemorrhagic events

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Pengo, V., Cucchini, U., Denas, G., Erba, N., Guazzaloca, G., La Rosa, L., De Micheli, V., Testa, S., Frontoni, R., Prisco, D., Nante, G., Iliceto, S., for the Italian Federation of Centers for the Diag, (2009). Standardized Low-Molecular-Weight Heparin Bridging Regimen in Outpatients on Oral Anticoagulants Undergoing Invasive Procedure or Surgery: An Inception Cohort Management Study. Circulation 119: 2920-2927 [Abstract] [Full Text]  
• Dentali, F., Riva, N., Malato, A., Saccullo, G., Siragusa, S., Ageno, W. (2009). Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.. J. Thorac. Cardiovasc. Surg. 137: 91-93 [Abstract] [Full Text]  
• Vahanian, A., Iung, B., Piérard, L., Dion, R., Pepper, J. (2009). CHAPTER 21 Valvular Heart Disease. ESC Textbook of Cardiovascular Medicine 2: med-9780199566990-chapter-med-9780199566990-chapter [Abstract] [Full Text]  
• Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., Ansell, J. (2008). The Perioperative Management of Antithrombotic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 299S-339S [Abstract] [Full Text]  
• Rivas-Gandara, N, Ferreira-Gonzalez, I, Tornos, P, Torrents, A, Permanyer-Miralda, G, Nicolau, I, Arellano-Rodrigo, E, Vallejo, N, Igual, A, Soler-Soler, J (2008). Enoxaparin as bridging anticoagulant treatment in cardiac surgery. Heart 94: 205-210 [Abstract] [Full Text]  
• Garcia, D. A., Regan, S., Henault, L. E., Upadhyay, A., Baker, J., Othman, M., Hylek, E. M. (2008). Risk of Thromboembolism With Short-term Interruption of Warfarin Therapy. Arch Intern Med 168: 63-69 [Abstract] [Full Text]  
• Spyropoulos, A. C. (2008). Outpatient-Based Primary and Secondary Thromboprophylaxis With Low-Molecular-Weight Heparin. CLIN APPL THROMB HEMOST 14: 63-74 [Abstract]  
• Shojania, A. M. (2007). Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin. ANN INTERN MED 147: 671-671 [Full Text]  
• O'Donnell, M. J., Kearon, C., Turpie, A. G. (2007). Bridging Low-Molecular-Weight Heparin for Temporary Interruption of Warfarin. ANN INTERN MED 147: 671-671 [Full Text]  
• Ruiz-Bailen, M., Narbona-Carvo, B., Ramos-Cuadra, J. A., Rucabado-Aguilar, L., Lopez-Caler, C., Gomez-Jimenez, F. J. (2007). Systemic thrombolysis for prosthetic valve thrombosis in the immediate postoperative period of major abdominal surgery. J. Thorac. Cardiovasc. Surg. 133: 801-803 [Full Text]  
• Authors/Task Force Members, , Vahanian, A., Baumgartner, H., Bax, J., Butchart, E., Dion, R., Filippatos, G., Flachskampf, F., Hall, R., Iung, B., Kasprzak, J., Nataf, P., Tornos, P., Torracca, L., Wenink, A., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Zamorano, J. L., Angelini, A., Antunes, M., Fernandez, M. A. G., Gohlke-Baerwolf, C., Habib, G., McMurray, J., Otto, C., Pierard, L., Pomar, J. L., Prendergast, B., Rosenhek, R., Uva, M. S., Tamargo, J. (2007). Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 0: ehl428v1-39 [Full Text]  
• Eckman, M. H. (2005). "Bridging On the River Kwai": The Perioperative Management of Anticoagulation Therapy. Med Decis Making 25: 370-373  
• Kovacs, M.J., Kearon, C., Rodger, M., Anderson, D.R., Turpie, A.G.G., Bates, S.M., Desjardins, L., Douketis, J., Kahn, S.R., Solymoss, S., Wells, P.S. (2004). Single-Arm Study of Bridging Therapy With Low-Molecular-Weight Heparin for Patients at Risk of Arterial Embolism Who Require Temporary Interruption of Warfarin. Circulation 110: 1658-1663 [Abstract] [Full Text]  
• Pocar, M., Assaghi, A., Donatelli, F. (2004). Use of enoxaparin in cardiac surgery. J. Thorac. Cardiovasc. Surg. 128: 327-328 [Full Text]  
• Douketis, J. D., Johnson, J. A., Turpie, A. G. (2004). Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin: Assessment of a Standardized Periprocedural Anticoagulation Regimen. Arch Intern Med 164: 1319-1326 [Abstract] [Full Text]